Entera Bio (ENTX) Return on Sales (2021 - 2025)

Entera Bio has disclosed Return on Sales across 5 years of filings, most recently posting 2.76% for Q4 2025.

• Quarterly Return on Sales fell 247.0% year-over-year to 2.76% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 2.76% (down 223.0% YoY) and the FY2025 annual result came in at 2.72%, down 220.0% from the prior year.
• Return on Sales slipped to 2.76% in Q4 2025, from 0.88% in the prior quarter.
• Over five years, Return on Sales peaked at 0.15% in Q1 2021 and troughed at 7.09% in Q3 2023.
• A 5-year average of 1.56% and a median of 0.68% in 2025 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2023 — Return on Sales plunged 410 bps — and 2024, when it jumped 637 bps.
• Tracing ENTX's Return on Sales over 5 years: stood at 0.25% in 2021, then plunged by 772 bps to 2.17% in 2022, then plunged by 227 bps to 7.09% in 2023, then jumped by 96 bps to 0.29% in 2024, then slumped by 860 bps to 2.76% in 2025.
• Business Quant data shows ENTX's Return on Sales at 2.76% in Q4 2025, 0.88% in Q3 2025, and 0.64% in Q2 2025.